u/customs_seizure_sid

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

fibrosis improvement without worsening steatohepatitis is the phrase to learn

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Does constipation follow the day after the shot, or is it spread across the week?

Kept every document including the dull ones.

Agreed — read the notice before deciding what has happened. Most of the panic here is misclassification.

staying at 1.7mg for an extra month is a legitimate plan

Minor fix — the half-life is about a week, not about a day. The rest of your point stands.

Are you measuring anything other than weight? Waist is usually the one that keeps moving.

Same experience with the appetite effect being flatter across the week rather than front-loaded.

Do you have a baseline from before you started?

Small fix — a reference interval is not a treatment target, and the post above uses them interchangeably.

Not convinced. You changed the dose and the week at the same time, so you cannot attribute the change to either.

the habits are what has to carry it afterwards

Substantial weight loss independently moves lipids, liver enzymes and several other markers. Attributing a change to a compound while losing weight is confounded by design.

Switching from semaglutide, since three people asked in this thread alone.

There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.

None of that is a recommendation. It is what the threads say, and the threads are not a clinic.

Small fix — those rules apply to commercial import. Personal import is governed separately and more narrowly.

Substantial weight loss independently moves lipids, liver enzymes and several other markers. Attributing a change to a compound while losing weight is confounded by design.

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

With a week-long half-life, exposure declines over several weeks after the last dose rather than stopping with it. The lag is why the first fortnight is uninformative.

My ferritin moved and I spent a fortnight convinced I knew why. The repeat six weeks later was back in range and I had changed nothing.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Country added to the title. Without it the answers will be confidently wrong.

Interval stretching lowers the trough concentration while keeping the dose; dose reduction lowers the level while keeping the rhythm. They are different interventions with different subjective profiles.

What step are you on and how long have you been there?

hold the dose that works, the ladder is not a leaderboard

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Address redacted from the screenshot above. Post the wording of the notice, never the header.

the habits are what has to carry it afterwards

research-use-only labelling is not a customs category

Correcting myself from earlier in the thread: I said week 10 and it was week 18. Same shape, wrong number.

Why this board insists on dates and documents rather than names.

A report that says "X is a scam" is unfalsifiable and unactionable. A report that says "ordered on this date, paid this way, asked for a batch document on this date, received this reply, nothing since" can be checked, corroborated, or corrected by somebody with a different experience.

The second kind has repeatedly turned out to be a shipping problem, a payment window, or a misread email. The first kind never turns into anything except an argument, and when it is wrong the cost falls on somebody real.

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

What this compound is actually being developed for, since the boards treat it as a weight-loss molecule with a footnote.

It is a dual GLP-1 and glucagon receptor agonist, and the glucagon arm links to hepatic fat and energy expenditure. The headline programme is metabolic liver disease, with endpoints scored on biopsy rather than on a scale.

That matters for how the data should be read. A histological response rate in a biopsy-confirmed population answers a very different question from a mean weight change in an obesity trial, and quoting one in place of the other — which happens in nearly every thread here — is not a comparison.

Where the evidence actually stands, since every thread here assumes a different answer.

Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.

Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.

the confidence interval is the finding, the point estimate is the headline

Biopsy-confirmed population or imaging-selected?

a fortnight of nothing is not evidence that you are fine

vial_math_vera is right that regain is a documented outcome rather than a character verdict.

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.